The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review : Therapeutic options - 15/08/19
![](/templates/common/images/mail.png)
![](/templates/common/images/mail.png)
Abstract |
Hyperhidrosis (HH) is a chronic disorder of excess sweat production that may have a significant adverse effect on quality of life. A variety of treatment modalities currently exist to manage HH. Initial treatment includes lifestyle and behavioral recommendations. Antiperspirants are regarded as the first-line therapy for primary focal HH and can provide significant benefit. Iontophoresis is the primary remedy for palmar and plantar HH. Botulinum toxin injections are administered at the dermal-subcutaneous junction and serve as a safe and effective treatment option for focal HH. Oral systemic agents are reserved for treatment-resistant cases or for generalized HH. Energy-delivering devices such as lasers, ultrasound technology, microwave thermolysis, and fractional microneedle radiofrequency may also be utilized to reduce focal sweating. Surgery may be considered when more conservative treatments have failed. Local surgical techniques, particularly for axillary HH, include excision, curettage, liposuction, or a combination of these techniques. Sympathectomy is the treatment of last resort when conservative treatments are unsuccessful or intolerable, and after accepting secondary compensatory HH as a potential complication. A review of treatment modalities for HH and a sequenced approach are presented.
Le texte complet de cet article est disponible en PDF.Key words : aluminum chloride hexahydrate, BTX, botulinum neurotoxin, botulinum toxin, compensatory sweating, endoscopic sympathectomy, fractional microneedle radiofrequency, hyperhidrosis, injectable therapy, iontophoresis, laser therapy, microwave thermolysis, oral anticholinergics, topical antiperspirants, ultrasound technology
Abbreviations used : ACH, BTX, HH, MU
Plan
Date of release: September 2019 |
|
Expiration date: September 2022 |
|
Funding sources: None. |
|
Conflicts of interest: None disclosed. |
Vol 81 - N° 3
P. 669-680 - septembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?